-

08:53:22 PM

SLGL Stock News

SLGL - Sol-Gel Technologies Ltd

09/22/21 7:30 AM

Nasdaq : SLGL

conferences

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will

RHEA-AI

neutral

09/09/21 8:30 AM

Nasdaq : SLGL

conferences

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will

RHEA-AI

neutral

08/04/21 7:05 AM

Nasdaq : SLGL

earnings

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Recently obtained FDA approval of TWYNEO ® triggers milestone payment from Galderma Exclusive license agreements with Galderma for U.S. commercialization of EPSOLAY ® and TWYNEO Sol-Gel adv ancing its early-stage pipeline in plaque psoriasis, palmoplantar keratoderma and other high-value

RHEA-AI

very positive

07/27/21 9:15 AM

Nasdaq : SLGL

fda approval

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

TWYNEO ® , a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038 Under a previously announced license, Sol-Gel to

RHEA-AI

very positive

07/20/21 7:05 AM

Nasdaq : SLGL

conferencesearnings

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter

RHEA-AI

neutral

06/28/21 5:10 AM

Nasdaq : SLGL

Sol-Gel Announces Pipeline Update and Future Development Plans

Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal model Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected

RHEA-AI

positive

06/28/21 5:00 AM

Nasdaq : SLGL

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.Under

RHEA-AI

positive

05/27/21 7:00 AM

Nasdaq : SLGL

conferences

Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced

RHEA-AI

neutral

05/13/21 7:05 AM

Nasdaq : SLGL

earnings

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY ® and TWYNEO ® - EPSOLAY PDUFA goal date was set for April 26, 2021. Awaiting FDA ’s pre-approval inspection - TWYNEO PDUFA goal date set for August 1, 2021 NESS ZIONA, Israel, May 13, 2021

RHEA-AI

neutral

04/27/21 10:02 AM

Nasdaq : SLGL

Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced an update

RHEA-AI

neutral

SLGL Data:

IndustryMedicinal and Botanical Manufacturing
Websitewww.sol-gel.com
CeoAlon Seri-Levy
Security nameSol-Gel Technologies Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees65
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
AddressWeizmann Science Park
StateNess Ziona
City7 Golda Meir
Zip7403650
CountryIsrael
Phone97289313433

SLGL Description:

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.